Taysha Gene Therapies (NASDAQ:TSHA) Price Target Lowered to $6.00 at Needham & Company LLC

Taysha Gene Therapies (NASDAQ:TSHA) had its target price decreased by Needham & Company LLC from $7.00 to $6.00 in a report issued on Monday morning, Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

TSHA has been the subject of a number of other reports. Cantor Fitzgerald reissued an overweight rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. Piper Sandler reduced their target price on shares of Taysha Gene Therapies from $9.00 to $7.00 and set an overweight rating for the company in a research note on Monday, July 1st. Jefferies Financial Group reaffirmed a buy rating and set a $8.00 price objective (up from $2.00) on shares of Taysha Gene Therapies in a research report on Tuesday, May 14th. BMO Capital Markets assumed coverage on shares of Taysha Gene Therapies in a research note on Thursday, June 27th. They set an outperform rating and a $5.00 price target for the company. Finally, Chardan Capital restated a buy rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, June 18th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat, Taysha Gene Therapies has an average rating of Buy and an average price target of $6.50.

Taysha Gene Therapies Trading Up 5.4 %

Taysha Gene Therapies stock traded up $0.11 during mid-day trading on Monday, hitting $2.15. The stock had a trading volume of 161,801 shares, compared to its average volume of 2,512,058. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.75. Taysha Gene Therapies has a 12 month low of $1.27 and a 12 month high of $4.32. The stock has a market capitalization of $402.09 million, a PE ratio of -4.16 and a beta of 0.41. The stock has a 50-day simple moving average of $2.62 and a two-hundred day simple moving average of $2.55.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. The firm had revenue of $3.41 million during the quarter, compared to analysts’ expectations of $3.70 million. During the same quarter in the previous year, the company earned ($0.28) earnings per share. As a group, sell-side analysts forecast that Taysha Gene Therapies will post -0.41 EPS for the current year.

Insider Activity at Taysha Gene Therapies

In other news, major shareholder Paul B. Manning bought 1,333,333 shares of the firm’s stock in a transaction on Thursday, June 27th. The shares were purchased at an average cost of $2.25 per share, with a total value of $2,999,999.25. Following the acquisition, the insider now directly owns 1,333,333 shares in the company, valued at $2,999,999.25. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 2.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. ADAR1 Capital Management LLC bought a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at approximately $370,000. Vanguard Group Inc. increased its holdings in shares of Taysha Gene Therapies by 235.2% during the third quarter. Vanguard Group Inc. now owns 5,327,864 shares of the company’s stock worth $16,836,000 after buying an additional 3,738,616 shares in the last quarter. Avoro Capital Advisors LLC lifted its stake in shares of Taysha Gene Therapies by 11.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 4,355,555 shares of the company’s stock valued at $7,709,000 after acquiring an additional 430,555 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at $28,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Taysha Gene Therapies during the 4th quarter worth $31,000. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.